Exploratory Clinical Evaluation of Personalized Functional Profiling in GI Tumors: Predicting Drug Response in CRC and PDAC

Sponsor
Luxembourg Institute of Health
Study ID
NCT07500259
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Personalized Functional Profiling — OTHER
    This is an observational study where biological samples are collected to provide Personalized Functional Profiling, an integrated strategy that combines genomic analysis with direct drug response assessments using patient-derived spheroids/organoids (PDSOs)

Study Details

The ColoPan study evaluates the scientific validity, reproducibility, and predictive performance of the Personalised Functional Profiling (PFP) platform in colorectal cancer and pancreatic ductal adenocarcinoma patients. It combines genomic sequencing with in vitro functional drug testing using patient-derived spheroids/organoids.

Key Dates

First listed
Mar 30, 2026
Start date
Jul 1, 2026
Status verified
Jun 2026
Primary completion
Sep 30, 2029
Completion
Nov 1, 2034

Study Design

Enrollment
188 participants (estimated)

Arms

  • Arm: CRC
    Participants are included while scheduled for biopsy or surgery of their colorectal cancer.
  • Arm: PDAC
    Participants are included while scheduled for biopsy or surgery of their cancer.

Primary Outcome Measure

PFP platform's predictive performance [ Time Frame: 0-5 years ]

Central Contacts

Find similar trials

Nationwide
Colorectal cancer trialsOncology trialsGI oncology trials

Related Studies